Recordati CEO sees ‘substantial opportunity’ in Sanofi drug purchase
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company’s purchase of Sanofi’s rare immune disorder drug, Enjaymo. Source link